Leading Innovation and Delivering 21st Century Medicines
SCIENCE
It's All in the Delivery:
Pioneering and innovative technology platform Delivering therapies and overcoming barriers
For years, delivering to the Central Nervous System (CNS) and taking therapies across the Blood-Brain Barrier (BBB) has impeded the efforts to find realistic and safe therapies for the CNS diseases. We have built SMDG's research and development platform on the guiding principles that a safe and effective delivery platform will allow scientists to create better and efficacious medicines for many neurological diseases and that an effective broad delivery platform will work for many other diseases too. With that in mind, we set out to design our technology platforms in order to create better medicines and more effective and safe therapies.
NanoLigand Carriers (NLC)
TM
A new Era of Peptide Conjugate Delivery Systems: NanoCarrier Ligands (NLC) are a new novel class of nanoparticles. NLCs are unique self-assembled peptidic/particulate systems that target the blood-brain barrier as well as other biological barriers. SMDG's innovative and patent-protected NLC technology could be used for targeted delivery of therapeutic and diagnostic agents. The NLC technology is based on "safe-by-design" and "simple-by-design" concepts that actively deliver therapeutic molecules to the target cells.
TM
TM
TM
TM
Other significant highlights and advantages of SMDG's R & D programs include simpler and faster manufacturing.
Sustainable and green: Much simpler manufacturing than the current industry delivery technology modalities, GMP compliant manufacturing technology and readily scalable.
How we do what we do
Therapeutic targets are studied, analyzed and evaluated based on disease effectiveness. We have already performed pre-clinical testing and analysis of our technology platform and library of peptide conjugate systems for delivering candidate therapeutic cargos.
Delivery of Genetic Medicine: Therapeutic cargos/nucleic acids are designed and evaluated both in in-vitro and in-vivo. Alternatively we collaborate with partners and utilize our proprietary peptide conjugate systems for delivery of other already characterized nucleic acid cargos and perform both in-vitro and in-vivo pre-clinical studies.
We design dual and single therapies and also focus on neuroinflammation for several therapeutic modalities.
